Work

Phase I dose-escalation results of 177 Lu-NYM032 in patients with progressive metastatic castration-resistant prostate cancer (mCRPC).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.5049

Authors: Yanjuan Wang, Lu Hou, Qiaoling Xu, Xiuqing Xue, Jie Pan, Hong Qi, Peng Fang, P. David Mozley, Alton Oliver Sartor, Chunjing Yu

Institutions: Wuxi Fourth People's Hospital, Yancheng First People's Hospital, Jiangnan University

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162559552

Cites:

Cited by:

Related to: